BIO
The table below shows Bio-Rad Laboratories, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $529.80M | $488.10M | $403.81M | $434.21M | $470.78M | $662.21M |
| Short-term investments | $1.01B | $1.18B | $1.20B | $1.36B | $399.13M | $328.91M |
| Receivables | $460.60M | $452.50M | $489.02M | $494.64M | $423.54M | $419.42M |
| Inventory | $740.70M | $760.00M | $780.52M | $719.32M | $572.24M | $622.25M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets | $2.91B | $3.03B | $3.05B | $3.16B | $1.99B | $2.14B |
| Property, plant & equipment | $539.90M | $528.10M | $529.01M | $498.61M | $490.95M | $491.37M |
| Goodwill | $579.80M | $410.50M | $413.57M | $406.49M | $347.34M | $291.92M |
| Total assets | $10.58B | $9.36B | $12.30B | $13.50B | $17.78B | $12.97B |
| Accounts payable | $129.00M | $122.30M | $144.63M | $135.04M | $141.94M | $139.45M |
| Total current liabilities | $517.00M | $467.80M | $522.80M | $568.71M | $680.94M | $631.54M |
| Long-term debt | $1.20B | $1.20B | $1.20B | - | - | - |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | $4.11B | $3.09B |
| Retained earnings | $8.18B | $7.42B | $9.26B | $9.90B | $13.51B | $9.27B |
| Total equity | $7.45B | $6.57B | $8.74B | $9.62B | $13.67B | $9.88B |